The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
== Education == He studied chemistry at the Eötvös Loránd University (Budapest), where he graduated in 1973 and received a PhD in biochemistry in 1976. He worked as a postdoctoral research fellow at the University of California, San Francisco in 1978-1979.
Xanthoria parietina serves as both a food source and shelter for certain gastropods. The snail Balea perversa uses the lichen for shelter and nourishment. Similarly, other gastropods, such as Helicigona lapicida, feed on Xanthoria parietina. This grazing may contribute to lichen dispersal: photobiont cells from X. parietina partially survive passage through the snail's digestive tract, retaining some photosynthetic activity even after digestion. Such survival raises the possibility that snail herbivory could facilitate lichen relichenization—either by recombining surviving symbionts from the same thallus or by mixing photobionts and mycobionts from different individuals in fecal deposits. However, digestion significantly reduces photobiont viability, with photobiont fluorescence (a measure of photosynthetic activity) declining by 41–44% after passage through the snail gut. While some cells remain intact, they often suffer morphological damage (including shrunken chloroplasts and enlarged cell wall-to-membrane distances), leaving it unclear whether surviving photobionts can effectively establish new lichens without viable fungal spores or hyphae.
==== Bone tissue ==== Bone defects or fractures can occur in a number of ways, including trauma, neoplasm, osteoporosis, or congenital disorders. Treatments such as autografts or allografts suffer from lack of donor sites and chance of communicable disease, respectively. There is therefore considerable interest in developing tissue engineered bone constructs, which should encourage tissue regeneration. Coating an implant with RGD has been shown to improve bone cell adhesion, proliferation and survival. In vivo studies of such coatings additionally demonstrated improved osseointegration. Modifying a titanium implant surface with a protein containing RGD improved bone mineralization and implant integration and prevented failure of the prosthetic.
According to provisions of the Government of India Act 1935, a bicameral legislature of Assam province came into existence in 1937. After the Government of India Act 1935 was passed, it paved the way for the formation of Assam Legislative Assembly, and became a bicameral legislature. The strength of the House was 108, where all the members were elected. The Legislative Council (Upper House) was not less than 21 and not more than 22 members. The first sitting of its lower house, the Assam Legislative Assembly, took place on 7 April 1937 in the Assembly Chamber at Shillong. Shillong was the capital of the composite State of Assam. It had a strength of 108 members. However, the strength of the Assembly was reduced to 71 after the partition of India. After Indian independence, the Assam Legislative Council was abolished in 1952 and the Assam Legislative Assembly became unicameral. The reconstituted assembly had 108 members with 31 seats reserved for Scheduled Tribes and Scheduled Castes. In the years that followed, Assam was truncated to several smaller states. And over the years, with the changing geographical boundaries and increase in population, the strength of members has changed from 108 in 1952–57 to 114 in 1967-72 (the third Assembly) and by 1972-78 (the fifth Assembly) it had a strength of 126 members.
Jammu and Kashmir (princely state), for the entity that existed till 1952 Kashmiriyat Kashmiri cinema Literature of Kashmir Music of Jammu and Kashmir Kus Bani Koshur Karorpaet AIR Srinagar Central University of Kashmir Central University of Jammu Jammu and Kashmir cricket team Real Kashmir F.C. Jammu and Kashmir football team Jammu and Kashmir Light Infantry Jammu and Kashmir Rifles Fauna of Jammu and Kashmir Mansar-Surinsar Wildlife Sanctuary
Sources: en.wikipedia.org
It also appeared in descriptions of the terrestrial agricultural practise of sub-irrigation in the late-19th century before becoming associated primarily with the cultivation of aquatic plant- and animal-species. (The Oxford English Dictionary records the common modern usage of "aquaculture" from 1887; and that of "aquiculture" from 1867.) In 1859, Stephen Ainsworth of West Bloomfield, New York, began experiments with brook trout. By 1864, Seth Green had established a commercial fish-hatching operation at Caledonia Springs, near Rochester, New York. By 1866, with the involvement of W. W. Fletcher of Concord, Massachusetts, artificial fish-hatcheries operated both in both Canada and in the United States. When the Dildo Island fish hatchery opened in Newfoundland in 1889, it was the largest and most advanced in the world. The word "aquaculture" was used in descriptions of the hatcheries experiments with cod and lobster in 1890. By the 1920s, the American Fish Culture Company of Carolina, Rhode Island, founded in the 1870s, was one of the leading producers of trout. During the 1940s, they perfected the method of manipulating the day- and night-cycle of fish so that they could be artificially spawned year-round. Californians harvested wild kelp and attempted to manage supply around 1900, later labeling it a wartime resource.
=== Applications === The triple-stranded DNA regions can be generated through the association of Triplex Forming Oligonucleotides (TFO) and Peptide Nucleic Acids (PNAs). Historically, TFO binding has been shown to inhibit transcription, replication, and protein binding to DNA. TFOs tethered to mutagens have also been shown to promote DNA damage and induce mutagenesis. Although TFO have been known to hinder transcription and replication of DNA, recent studies have shown that TFO can be utilized to mediate site specific gene modifications both in vitro and in vivo. Another recent study has also shown that TFOs can be used for suppression of oncogenes and proto-oncogenes to reduce cancer cell growth. For example, a recent study has used TFOs to reduce cellular death in hepatoma cells through the decreasing the expression of MET. PNA TFOs have the ability to enhance recombination frequencies, leading to targeted, specific editing of genes. The PNA-DNA-PNA triplex helix is able to be recognized by the cell's own DNA repair mechanism, which sensitizes the surrounding DNA for homologous recombination. In order for a site-specific PNA structure to mediate recombination within a DNA sequence, a bis-PNA structure can be coupled with a 40nt DNA fragment that is homologous to an adjacent region on the target gene. The linking of a TFO to a donor DNA strand has been shown to induce recombination of the targeted gene and the adjacent gene target region.
Methylephedrine, sold under the brand name Metheph among others, is a sympathomimetic medication described as an antiasthmatic agent and used to treat coughing and nasal congestion. It is reported to be used in various over-the-counter cough and cold preparations throughout the world, including Japan. The drug is an ephedrine-like sympathomimetic and activates α- and β-adrenergic receptors. Chemically, it is a substituted amphetamine and is closely related to ephedrine. Methylephedrine was discovered by 1927. It is mostly no longer marketed as a prescription drug. The drug is also found naturally as an alkaloid in Ephedra species including Ephedra sinica, Ephedra vulgaris, and Ephedra distachya.
6 February – Former Chancellor of the Exchequer Kwasi Kwarteng announced he is stepping down from Parliament at the next election. The UK government gives Birmingham City Council to go-ahead to increase its Council Tax by 10% from April. Welsh Government minister Hannah Blythyn announces that the Welsh Government is taking over South Wales Fire and Rescue Service after it was found to have a culture of harassment and misogynism. Elena Whitham resigns from the post of Minister for Drugs and Alcohol Policy for health reasons. Former prime minister Liz Truss launches a campaign to "galvanise" the UK's "secret Conservatives" and fight back against the "left wing extremists" she says have taken over the UK's institutions. 7 February – Sunak faced a call from a Labour MP to apologise after he ridiculed Starmer over his U-turn on "defining a woman" at Prime Minister's Questions. Met Office data obtained by BBC Verify raises questions over UK government suggestions that poor weather conditions had no impact on a fall in English Channel migrant crossings during 2023. The number of crossings were fewer than during the previous year, which the government had said was nothing to do with the weather, but the figures suggest there were fewer days during 2023 when compared to 2022 when migrants could successfully cross the Channel. 8 February – Labour scraps its plans for a £28bn annual green investment, with Sir Keir Starmer saying the policy is unaffordable because of the Conservatives' economic record.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.